Cardiometabolic risk increases significantly during the menopausal transition, creating unique challenges for women with obesity. This session will explore the intersection of menopause, cardiovascular health, and menopausal hormonal therapy (MHT) through an obesity medicine lens. Attendees will learn how to evaluate women at different stages of menopause, assess individualized risks, and understand when menopausal hormone therapy can reduce cardiovascular risk versus when it may cause harm. With a focus on practical application, the session will review evidence-based guidance, patient profiles, and real-world scenarios to support safe, informed, and personalized use of hormonal therapy in women with obesity.

CME/CE Expiration Date: 4/9/29

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.